Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 5/20 | 0.40 |
| ▸ | CDK2 | P24941 | 5/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | YES1 | P07947 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 3/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.37 |
| ▸ | CCND1 | P24385 | 3/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6417047 | 0.80 | EGFR (0.66) | EGFRCLK4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15507986 | 0.76 | PTGS2 (0.43) | TTKPTGS1PTGS2MEN1KMT2A | |
| SCHEMBL30132240 | 0.76 | PTGS2 (0.43) | TTKPTGS1PTGS2MEN1KMT2A | |
| SCHEMBL30132191 | 0.75 | TTK (0.58) | CDK2TTK | |
| SCHEMBL15507757 | 0.75 | TTK (0.58) | CDK2TTK | |
| SCHEMBL21572096 | 0.75 | TLR9 (0.37) | TTKMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL30132220 | 0.74 | TTK (0.46) | CDK1CDK2TTKPTGS1PTGS2 | |
| SCHEMBL17024302 | 0.74 | TTK (0.46) | CDK1CDK2TTKPTGS1PTGS2 | |
| SCHEMBL6998196 | 0.74 | EGFR (0.57) | EGFRKDM1ACLK4CYP1A2CYP3A4 | |
| SCHEMBL5257326 | 0.73 | SYK (0.46) | CDK1CDK2KDRALKKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897877-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-02-13 | — | — | US | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| US-11046688-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| US-20200165241-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10479788-B2 | Compounds that inhibit MPS1 kinase | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-11-19 | — | — | US | disclosed |
| EP-3293183-B1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20180141944-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-05-24 | — | — | US | disclosed |
| EP-3293183-A1 | INHIBITOR COMPOUNDS | Cancer Research Technology Ltd. (GB) | 2018-03-14 | — | — | EP | disclosed |
| US-9890157-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-13 | — | — | US | disclosed |
| US-9834552-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| EP-2892889-B1 | INHIBITOR COMPOUNDS | CANCER RES TECH LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-9409907-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-09 | — | — | US | disclosed |
| US-20160222009-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160220570-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20150239884-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
| EP-2892889-A1 | INHIBITOR COMPOUNDS | Cancer Research Technology Ltd (GB) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014037750-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479788-B2 | Compounds that inhibit MPS1 kinase | BUB1B, BUB1, CDK1 | EGFR 1841/4885CDK1 3/4885CDK2 57/4885 |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | EGFR 1975/4885CDK1 3/4885CDK2 50/4885 |
| US-20150239884-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | EGFR 1975/4885CDK1 3/4885CDK2 50/4885 |
| US-11046688-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | EGFR 1975/4885CDK1 3/4885CDK2 50/4885 |
| US-20180141944-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | EGFR 1975/4885CDK1 3/4885CDK2 50/4885 |
| US-20160222009-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | EGFR 1975/4885CDK1 3/4885CDK2 50/4885 |
| US-11897877-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | EGFR 1975/4885CDK1 3/4885CDK2 50/4885 |
| US-20200165241-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | EGFR 1975/4885CDK1 3/4885CDK2 50/4885 |
| US-20160220570-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | EGFR 1975/4885CDK1 3/4885CDK2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.